Safety and efficacy of rebamipide compared to artificial tears for the treatment of dry eye: a systematic review and meta-analysis.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

BMC Ophthalmology Pub Date : 2025-05-27 DOI:10.1186/s12886-025-04146-0

Ching-Wen Chiu, Ka-Wai Tam, I-Chan Lin

{"title":"Safety and efficacy of rebamipide compared to artificial tears for the treatment of dry eye: a systematic review and meta-analysis.","authors":"Ching-Wen Chiu, Ka-Wai Tam, I-Chan Lin","doi":"10.1186/s12886-025-04146-0","DOIUrl":null,"url":null,"abstract":"Background: Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic efficacy of topical RBM for dry eye disease (DED) treatment remains inconclusive. Accordingly, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the effectiveness of RBM for DED treatment.Methods: We searched the PubMed, Embase, and Cochrane Library databases for eligible RCTs. The primary outcome was posttreatment changes in tear breakup time (TBUT). We also assessed changes in the values of Schirmer's test (Sch), corneal fluorescein staining scores, and DED-related symptom scores.Results: We retrieved 12 RCTs with 1368 eyes published during 2012-2023. The results demonstrated that compared with artificial tears, 2% RBM significantly increased the TBUT [standard mean difference (SMD) = 1.42, 95% confidence interval (CI) = 0.20 to 2.64]. Moreover, 2% RBM led to more significant improvements in overall DED-related symptom scores than did artificial tears (SMD = - 1.61, 95% CI = - 2.61 to - 0.61). The differences in the adverse events between the 2% RBM and artificial tears groups were nonsignificant (SMD = 1.23, 95% CI = 0.62 to 2.44).Conclusion: Topical RBM ophthalmic suspension is a safe and effective treatment for DED patients. Compared to artificial tears, 2% RBM improved TBUT and subjective symptoms of DED. It may be considered as the first-line treatment option for short- TBUT dry eye patients.","PeriodicalId":9058,"journal":{"name":"BMC Ophthalmology","volume":"25 1","pages":"317"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107901/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12886-025-04146-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Rebamipide (RBM) is a novel drug that increases mucin secretion on the ocular surface. Nevertheless, the therapeutic efficacy of topical RBM for dry eye disease (DED) treatment remains inconclusive. Accordingly, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the effectiveness of RBM for DED treatment.

Methods: We searched the PubMed, Embase, and Cochrane Library databases for eligible RCTs. The primary outcome was posttreatment changes in tear breakup time (TBUT). We also assessed changes in the values of Schirmer's test (Sch), corneal fluorescein staining scores, and DED-related symptom scores.

Results: We retrieved 12 RCTs with 1368 eyes published during 2012-2023. The results demonstrated that compared with artificial tears, 2% RBM significantly increased the TBUT [standard mean difference (SMD) = 1.42, 95% confidence interval (CI) = 0.20 to 2.64]. Moreover, 2% RBM led to more significant improvements in overall DED-related symptom scores than did artificial tears (SMD = - 1.61, 95% CI = - 2.61 to - 0.61). The differences in the adverse events between the 2% RBM and artificial tears groups were nonsignificant (SMD = 1.23, 95% CI = 0.62 to 2.44).

Conclusion: Topical RBM ophthalmic suspension is a safe and effective treatment for DED patients. Compared to artificial tears, 2% RBM improved TBUT and subjective symptoms of DED. It may be considered as the first-line treatment option for short- TBUT dry eye patients.

查看原文本刊更多论文

与人工泪液相比，利巴米胺治疗干眼症的安全性和有效性：一项系统综述和荟萃分析。

背景：利巴米胺（RBM）是一种增加眼表黏液分泌的新型药物。然而，局部RBM治疗干眼病（DED）的疗效仍不确定。因此，我们对随机对照试验（rct）进行了系统回顾和荟萃分析，以调查RBM治疗DED的有效性。方法：检索PubMed、Embase和Cochrane图书馆数据库，寻找符合条件的随机对照试验。主要观察指标为治疗后泪液破裂时间（TBUT）的变化。我们还评估了Schirmer试验（Sch）值、角膜荧光素染色评分和ded相关症状评分的变化。结果：我们检索了2012-2023年间发表的12项随机对照试验，共1368只眼睛。结果显示，与人工泪液相比，2% RBM显著提高TBUT[标准均差(SMD) = 1.42, 95%可信区间(CI) = 0.20 ~ 2.64]。此外，与人工泪液相比，2% RBM在ded相关症状评分方面的改善更为显著（SMD = - 1.61, 95% CI = - 2.61至- 0.61）。2% RBM组和人工泪液组不良事件的差异无统计学意义（SMD = 1.23, 95% CI = 0.62 ~ 2.44）。结论：局部RBM眼悬液是治疗DED患者安全有效的方法。与人工泪液相比，2% RBM改善了TBUT和DED的主观症状。它可能被认为是短TBUT干眼症患者的一线治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Ophthalmology OPHTHALMOLOGY-

CiteScore

3.40

自引率

5.00%

发文量

441

审稿时长

6-12 weeks

期刊介绍： BMC Ophthalmology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of eye disorders, as well as related molecular genetics, pathophysiology, and epidemiology.